{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:47:57Z","timestamp":1783028877651,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research on clinical cure and related mechanisms of chronic hepatitis B in infants and children aged 1-12 years and adults","award":["2023YFC2308102"],"award-info":[{"award-number":["2023YFC2308102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12247-w","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:15:04Z","timestamp":1765041304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Yunlian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"12247_CR1","unstructured":"Organization WH. Global tuberculosis report 2024. Geneva: World Health Organization. 2024."},{"issue":"4","key":"12247_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","volume":"2","author":"K Dheda","year":"2014","unstructured":"Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321\u201338.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"12247_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4103\/ijmr.IJMR_1961_16","volume":"147","author":"AKH Kumar","year":"2018","unstructured":"Kumar AKH, Chandrasekaran V, Kannan T, Lavanya J, Swaminathan S, Ramachandran G. Intrapatient variability in plasma rifampicin & Isoniazid in tuberculosis patients. Indian J Med Res. 2018;147(3):287\u201392.","journal-title":"Indian J Med Res"},{"issue":"1","key":"12247_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.00693-15","volume":"60","author":"JS Park","year":"2016","unstructured":"Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. Serum levels of antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob Agents Chemother. 2016;60(1):92\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"12247_CR5","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1093\/jac\/dkv148","volume":"70","author":"L Baietto","year":"2015","unstructured":"Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D\u2019Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. J Antimicrob Chemother. 2015;70(9):2572\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"12247_CR6","first-page":"718","volume":"18","author":"Chinese Medical Association","year":"2019","unstructured":"Chinese Medical Association, Chinese Medical Journals Publishing House; Chinese Society of General Practice. Guidelines for primary care of tuberculosis (Practice Edition\u00b72018). Chin J Gen Practitioners. 2019;18(8):718\u201322.","journal-title":"Chin J Gen Practitioners"},{"key":"12247_CR7","doi-asserted-by":"crossref","unstructured":"Gafar F, Wasmann RE, McIlleron HM, Aarnoutse RE, Schaaf HS, Marais BJ, Agarwal D, Antwi S, Bang ND, Bekker A, et al. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. Eur Respir J. 2023;61(3).","DOI":"10.1183\/13993003.01596-2022"},{"key":"12247_CR8","volume-title":"Rapid advice: treatment of tuberculosis in children","author":"WHO Guidelines Approved by the Guidelines Review Committee. In","year":"2010","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. In. Rapid advice: treatment of tuberculosis in children. edn. Geneva: World Health Organization; 2010."},{"key":"12247_CR9","unstructured":"Hospital BC. Capital medical university, editorial board of the chinese journal of antituberculosis. Expert Consensus on the Clinical Application of Therapeutic Drug Monitoring for Antituberculosis Agents[J]. *Chinese Journal of Antituberculosis. 2021;43(9):867\u2013873."},{"issue":"4","key":"12247_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/0394632017733638","volume":"30","author":"G Chen","year":"2017","unstructured":"Chen G, Wu SQ, Feng M, Wang Y, Wu JC, Ji GY, Zhang MM, Liu QQ, He JQ. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han. Int J Immunopathol Pharmacol. 2017;30(4):434\u20138.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"8","key":"12247_CR11","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1128\/AAC.00756-15","volume":"59","author":"MG Sturkenboom","year":"2015","unstructured":"Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW. Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of Rifampin in patients with tuberculosis. Antimicrob Agents Chemother. 2015;59(8):4907\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"12247_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijid.2014.12.001","volume":"32","author":"G Sotgiu","year":"2015","unstructured":"Sotgiu G, Alffenaar JW, Centis R, D\u2019Ambrosio L, Spanevello A, Piana A, Migliori GB. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis. 2015;32:101\u20134.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"12247_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1086\/598192","volume":"48","author":"H McIlleron","year":"2009","unstructured":"McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48(11):1547\u201353.","journal-title":"Clin Infect Dis"},{"key":"12247_CR14","unstructured":"Organization WH. Guidance for national tuberculosis programmes on the management of tuberculosis in children: web annex: evidence summary tables. In: Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed: web annex: evidence summary tables. edn. 2014."},{"issue":"4","key":"12247_CR15","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/AAC.02600-15","volume":"60","author":"A Bekker","year":"2016","unstructured":"Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and ethambutol in infants dosed according to revised WHO-Recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60(4):2171\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"12247_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","volume":"45","author":"IH Bartelink","year":"2006","unstructured":"Bartelink IH, Rademaker CM, Schobben AF, Van Den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and Pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077\u201397.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"12247_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1128\/AAC.50.2.407-413.2006","volume":"50","author":"SM Graham","year":"2006","unstructured":"Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of Pyrazinamide and ethambutol in children with tuberculosis and impact of Age, nutritional Status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50(2):407\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"12247_CR18","first-page":"1106","volume":"13","author":"S Thee","year":"2009","unstructured":"Thee S, Detjen A, Wahn U, Magdorf K. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis. 2009;13(9):1106\u201311.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"12247_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/tmi.12003","volume":"17","author":"LM Verhagen","year":"2012","unstructured":"Verhagen LM, L\u00f3pez D, Hermans PW, Warris A, de Groot R, Garcia J, de Waard JH, Aarnoutse RE. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Tropical Med Int Health. 2012;17(12):1449\u201356.","journal-title":"Tropical Med Int Health"},{"issue":"9","key":"12247_CR20","first-page":"965","volume":"11","author":"S Thee","year":"2007","unstructured":"Thee S, Detjen A, Quarcoo D, Wahn U, Magdorf K. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis. 2007;11(9):965\u201371.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"12247_CR21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1128\/AAC.04338-14","volume":"59","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran G, Kumar AH, Bhavani P, Kannan T, Kumar SR, Gangadevi NP, Banurekha V, Sekar L, Ravichandran N, Mathevan G. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. Antimicrob Agents Chemother. 2015;59(2):1162\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"12247_CR22","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12879-021-06764-7","volume":"21","author":"C Tersigni","year":"2021","unstructured":"Tersigni C, Boiardi G, Tofani L, Venturini E, Montagnani C, Bortone B, Bianchi L, Chiappini E, Cassetta MI, Fallani S, et al. Real-life Isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis. BMC Infect Dis. 2021;21(1):1087.","journal-title":"BMC Infect Dis"},{"key":"12247_CR23","doi-asserted-by":"crossref","unstructured":"Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicol\u00f2 A, Piccioni P, et al. Rifampicin and Isoniazid maximal concentrations are below Efficacy-associated thresholds in the majority of patients: time to increase the doses? Int J Antimicrob Agents. 2021;57(3).","DOI":"10.1016\/j.ijantimicag.2021.106297"},{"issue":"8","key":"12247_CR24","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/AAC.01474-06","volume":"51","author":"AH Diacon","year":"2007","unstructured":"Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose Rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"12247_CR25","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, et al. A dose-ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"12247_CR26","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dky152","volume":"73","author":"KE Stott","year":"2018","unstructured":"Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-M\u00e9ndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(9):2305\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"12247_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","volume":"58","author":"AA Abulfathi","year":"2019","unstructured":"Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet. 2019;58(9):1103\u201329.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"12247_CR28","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/jac\/dkab336","volume":"76","author":"AJ Garcia-Prats","year":"2021","unstructured":"Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, Masenya M, Schaaf HS, Wiesner L, Norman J, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother. 2021;76(12):3237\u201346.","journal-title":"J Antimicrob Chemother"},{"key":"12247_CR29","unstructured":"Cui JX, Guan W, Feng XY. Research progress on the association between N-Acetyltransferase 2 gene polymorphisms and Isoniazid-Induced liver injury. China Healthc Frontier. 2013(9):16\u20138."},{"issue":"4","key":"12247_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.apsb.2017.05.003","volume":"7","author":"MA Doll","year":"2017","unstructured":"Doll MA, Salazar-Gonz\u00e1lez RA, Bodduluri S, Hein DW. Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of Isoniazid in cryopreserved human hepatocytes. Acta Pharm Sin B. 2017;7(4):517\u201322.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"12247_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cpt.778","volume":"103","author":"RJ Svensson","year":"2018","unstructured":"Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH. A population Pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clin Pharmacol Ther. 2018;103(4):674\u201383.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12247-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:03:08Z","timestamp":1768269788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12247-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12247"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12247-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of West China Second University Hospital, Sichuan University (Approval Registration Number\u20142024347)). Due to the retrospective nature of the study and the use of anonymized clinical data for analysis, the requirement for informed consent was waived by the Ethics Committee. Throughout the research process, participant privacy and confidentiality were strictly maintained. All scientific procedures complied with the ethical standards of West China Second University Hospital, Sichuan University, and the principles of the Declaration of Helsinki (1975).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}